Gilead Sciences Inc., of Foster City, Calif., said its marketing authorization application (MAA) for sofosbuvir was validated by the European Medicines Agency (EMA) and is under assessment

Gilead Science Inc.'s oral targeted cancer drug, idelalisib (GS-1101), made a splash last week when the American Society of Clinical Oncology (ASCO) unveiled thousands of abstracts scheduled for presentation at next week's annual meeting in Chicago

The company also has GEMS drug discovery deals with Celgene Corp., Gilead Sciences Inc. (through its acquisition of CV Therapeutics Inc.) and Merck & Co

and acquired by Gilead Sciences Inc

Gilead Sciences Inc., of Foster City, Calif., reported results from a Phase II study (Study 101-08) evaluating idelalisib (formerly GS-1101), an investigational, targeted, oral inhibitor of PI3K delta, in combination with rituximab for older patients with treatment-naïve chronic lymphocytic leukemia

Gilead Sciences Inc. (Foster City, Calif.) GS-7977 Sofosbuvir Hepatitis C virus genotypes 2 and 3, and genotypes 1, 4, 5 or 6 In three randomized trials, the rate of sustained virologic response after 12 weeks ranged from 50% for treatment-experienced patients to 78% for patients who were unwilling or unable to take interferon

Gilead Sciences Inc. (Foster City, Calif.) Elvitegravir and cobicistat Integrase inhibitor and a boosting agent designed to increase blood levels of certain protease inhibitors HIV Received complete response letters for the NDAs 4/30/13 Gilead Sciences Inc. (Foster City, Calif.) Sofosbuvir Once-daily oral nucleotide analogue Chronic hepatitis C virus infection Submitted an NDA 4/10/13 RESPIRATORY Theravance Inc. (South San Francisco) and GlaxoSmithKline plc (London) Breo Fluticasone furoate (FF

Gilead's Pipeline Overshadows Earnings Miss In its first-quarter earnings call, Gilead Sciences Inc

Gilead Sciences Inc., of Foster City, Calif., reported interim results from its Phase II LONESTAR study evaluating eight- and 12-week courses of therapy with the once-daily fixed-dose combination tablet of sofosbuvir and ledipasvir, with and without ribavirin (RBV), in 60 genotype 1, treatment-naïve, noncirrhotic hepatitis C virus (HCV) patients

Gilead Sciences Inc., of Foster City, Calif., said it received complete response letters (CRLs) from the FDA for its new drug applications for elvitegravir and cobicistat to use as part of HIV treatment regimens

Gilead Sciences Inc. $1B bluebird bio Celgene Corp. $225M The Medicines Co

At this point, the leader of the pack appears to be Gilead Sciences Inc.'s sofosbuvir (GS-7977

inked a deal with Gilead Sciences Inc., of Foster City, Calif., to develop drugs for up to four targets using MacroGenics' Dual-Affinity Re-Targeting (DART) technology

The fortunes of the leading biotechnology companies in this time period has been nothing less than spectacular with the share prices of Amgen Inc. (+104 percent), Gilead Sciences Inc. (+430 percent), Celgene Corp. (+107 percent) and Biogen Idec Inc. (+294 percent) exhibiting significant gains in their share prices...Heading into BIO 2013, according to BioWorld Insight analysis, large biotech companies, with market caps greater than $1 billion, have collectively seen their share prices jump by an

Gilead Sciences Inc., Biogen Idec Inc

Gilead Sciences Inc. (Foster City, Calif.) Stribild Composed of elvitegravir, cobicistat and Truvada (emtricitabine and tenofovir disoproxil) HIV Received a positive opinion from the EMA's CHMP 3/25/13 Hemispherx Biopharma Inc. (Philadelphia) Naturaferon Alferon N injection Genital warts Argentina approved its use in patients who fail or become intolerant to treatment with recombinant interferon 3/5/13 Medigene AG (Martinsried, Germany) Veregen Sinecatechins 15% External genital warts Obtained

Gilead Sciences Inc. (Foster City, Calif.) TAF Single tablet containing tenofovir alafenamide HIV Phase II data showed it was similar to Stribild 3/6/13 Medivir AB (Huddinge, Sweden) and Gilead Sciences Inc. (Foster City, Calif.) Sofosbuvir Nucleotide inhibitor

Gilead Sciences Inc., of Foster City, Calif., completed an $11.2 billion acquisition of Princeton-based Pharmasset Inc., and Amgen Inc...Also in the quarter Gilead Sciences Inc